摘要
Abstract
OBJECTIVE:To probe into the efficacy and safety of different dosages of rosuvastatin in treatment of reperfusion injury after acute myocardial infarction ( AMI) . METHODS:128 patients with reperfusion injury after AMI admitted into Wujin Hospital Affiliated to Jiangsu University from Jun. 2015 to May 2016 were retrospective selected and divided into observation group and control group according to different treatment methods, with 64 cases in each group. The observation group was treated with 20 mg of rosuvastatin for once a day, while the control group was given 10 mg of rosuvastatin for once a day. Serum lipid parameters, angiography results, levels of interleukin 18 (IL-18), contents of adiponectin and incidences of adverse drug reactions of two groups before and after treatment were observed. RESULTS: After treatment, total cholesterol, triacylglycerol, levels of low density lipoprotein ( LDL ) , incidence of single vascular occlusion and levels of IL-18 of both groups were significantly lower than those of before treatment, and those of observation group were significantly lower than the control group; levels of high density lipoprotein ( HDL) and contents of adiponectin of both groups were significantly higher than those of before treatment, and those of observation group were significantly higher than the control group, with statistically significant differences (P<0. 05). No obvious adverse drug reactions were found in both groups. CONCLUSIONS:Rosuvastatin can effectily relieve the inflammatory reactions of reperfusion injury after AMI, and promote the recovery of cardiac function. Besides, the efficacy of dosage of 20 mg/d is better than that of 10 mg/d.关键词
急性心肌梗死/瑞舒伐他汀/再灌注损伤Key words
Acute myocardial infarction/Rosuvastatin/Reperfusion injury分类
医药卫生
